Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (211)	7/19/1998 2:15:00 PM
From: scaram(o)uche	Read Replies (4) \| Respond to of 4974

An opportunity..... The absolute bejeezuz has been beaten out of second- and third-tier biotech. Although those who do not know the industry may not agree (and largely dictate overall sentiment), there are bargains galore. At the same time, the underwriting business is changing. The houses that traditionally underwrite biotech have been picked off (e.g., Robertson Stephens) or are on the blocks (e.g., H&Q). They will increasing compete for big deals and ignore the companies that need $15-40 million. B.S. Underwriters, Inc. (Biotech-SiliconInvestor Underwriters, Inc.) Perfect timing...... without a bank, smaller companies and valuable technology will be picked off before the public ever gets a chance to profit from it. Other companies, like BTRN, already have money..... they have a different sort of problem...... not only are they outside of the purview of the larger underwriters, they don't need the "Cowen and Co.s of the world". This presents an op to merge small companies with complementary technologies. If there are lurkers out there with relevant banking and/or counsel experience, why not start a new boutique, sort of like Drake spun out Vector? The timing is perfect, and the world's best biotech analysis is found here at SI.